Brussels : Actualité Brussels en direct - P2 | Bourse Reflex
Accueil > Tags > Brussels

  • Toutes les actualités en rapport avec « Brussels »

10/03 18:30 Brussels - GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016

09/03 18:00 Brussels - Declaration according to article 223-16 (AMF)

08/02 18:00 Brussels - Declaration according to article 223-16 (AMF)

27/01 18:40 Brussels - GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

26/01 18:00 Brussels - 2015/16 nine-month revenues up 25% - Full-year growth objectives raised for the second time this year

25/01 18:00 Brussels - BUSINESS UPDATE - FOURTH QUARTER 2015

11/01 08:30 Brussels - GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016

07/01 07:30 Brussels - GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS(R) HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

05/01 19:00 Brussels - Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development

02/12 18:00 Brussels - Benedikt Timmerman resumes CEO position at Genticel

29/10 18:00 Brussels - Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections

28/10 18:45 Brussels - Business Update - Third Quarter 2015

21/09 17:40 Brussels - Genticel presents first half 2015 financial results, operational progress and outlook

08/09 07:30 Brussels - US patent granted for use of Genticel's antigen delivery vectors in combination therapy to treat cancer

01/09 18:00 Brussels - GENTICEL to meet investors

28/07 18:00 Brussels - Business Update - Second Quarter 2015

07/07 18:00 Brussels - Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

02/07 18:15 Brussels - Genticel CFO, Martin Koch, Appointed CEO to Replace Benedikt Timmerman during Temporary Medical Leave of Absence

16/06 07:00 Brussels - Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

01/06 07:00 Brussels - Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform